MUIH has submitted the Post-Baccalaureate Certificate in Cannabis Science: Therapeutics, Product Design, and Quality Assurance program to the Maryland Higher Education Commission (MHEC) for approval. This program will begin in fall 2020, pending MHEC approval. Applications are currently being accepted; in the event that the program is not approved by MHEC, all fees will be refunded to applicants.
The Post-Baccalaureate Certificate in Cannabis Science: Therapeutics, Product Design, and Quality Assurance is one of the few graduate programs in the U.S. to focus on cannabis and to support this rapidly growing industry. The program educates students about cannabis-based products with an emphasis on health effects, safety, formulation, and quality assurance. The program addresses CBD-dominant hemp-based dietary supplements and wellness products, as well as THC-dominant medical and recreational marijuana. The program is 15 credits, can be completed in 1 year, and is delivered fully online.
This program is designed for individuals who wish to promote evidence-informed, safe, and responsible use of high-quality cannabis-based products. The program is ideal for those seeking an initial career in the cannabis industry or looking to expand their job options within the field. The program is also designed for conventional and integrative health practitioners interested in learning about cannabis in order to be informed for their clients.
The Post-Baccalaureate Certificate in Cannabis Science: Therapeutics, Product Design, and Quality Assurance educates students about cannabis-based products with an emphasis on health effects, safety, formulation, and quality assurance. The program integrates the traditional herbal medicine knowledge and evidence-informed cannabis research needed to develop innovative strategies for commercializing safe and effective cannabis products. Unique to this program, students will investigate ways to combine cannabis with other herbs to optimize health benefits and reduce risks.
The program provides education in the following areas:
This is a non-experiential program. There are no internships, laboratories, field work, or hands on work with cannabis as part of this curriculum and program.
The program includes a scientific exploration of two distinct sets of cannabis-based products. The first group is the CBD-dominant hemp-based products that are not psychoactive, are legal in all fifty U.S. states, and are being integrated increasingly into the dietary supplement industry. The second set of products are medical and recreational THC-dominant cannabis products that are psychoactive, regulated more strictly than hemp-based products, and mostly available through a limited number of licensed dispensaries. The program examines the science behind cannabis and explores the evidence for therapeutic benefits and risks, considerations in product design, and issues of quality assurance for both types of products.
With regards to CBD-dominant hemp-based products, students including complementary and integrative health (CIH) practitioners will learn how to assess products on the market and safely and appropriately recommend those that are well-designed and meet quality control standards. Students interested in product design or other work in the dietary supplement industry, will learn the principles of formulation and quality assurance for purposes of evaluating existing products and product development.
Recommending THC-dominant cannabis products does not fall within the scope of practice for most CIH practitioners; however, many clients are consuming or considering consuming THC-dominant products. It is important that CIH practitioners be well informed about quality, safety, and effectiveness of THC-dominant cannabis products in order to identify safety concerns as well as refer to other clinicians when appropriate. Students interested in working in licensed dispensaries will also benefit from this education as it provides them with the tools to evaluate retail products, build quality control practices into the dispensary workflow, and inform customers about available products in an ethical and responsible fashion.
Like other MUIH programs, this one is designed to serve students with and without a background in science or medicine. Courses are designed to scaffold learning, knowledge, and skills in ways that meet students’ prior educational levels in the sciences. Courses and instruction are also designed to respect and incorporate students’ workplace experiences, and to build upon them and enrich the course for others.
Through this graduate-level academic program students will also gain the foundational skills that employers seek and that can establish them as leaders in their field, and which are not typically provided by non-credit training programs. This includes skills such as critical thinking, problem solving, and research literacy.
Upon completion of the program graduates will be able to:
The program consists of 15 credits of the following required courses:
HRB 610 The Endocannabinoid System and Phytocannabinoids (3 cr)
Understanding the endocannabinoid system provides a foundation for rational cannabis therapeutics and formulation. Learn the role and mechanisms of the endocannabinoid system in regulating biological functions in health and disease. Gain an understanding of the basic components of the endocannabinoid system including different types of cannabinoids and cannabinoid receptors. Explore endogenous cannabinoids made by the body as well as the modulatory effects of phytocannabinoids (e.g., THC and CBD) from cannabis and other medicinal plants.
HRB 611 Cannabis Therapeutics (3 cr)
Identify balanced research summaries for pharmacological, toxicological, and clinical research on cannabis with attention to different cannabis chemotypes and phytochemicals. Describe the evidence base for cannabis as a therapeutic intervention for disease and illness and as a tool for promoting health and well-being. Examine evidence and research gaps regarding both benefits and risks of cannabis use. Utilize current evidence to identify safe and effective cannabis-based therapies and inform decision making in case studies.
HRB 612 Cannabis Dispensary Practices (3 cr)
This course combines the rigor of quality control with whole-system operational policies and procedures in a retail context. Learn best practices in dispensary operations to provide a range of safe and effective high-quality cannabis-based products to meet community needs. Use an ethical and legal framework to communicate professionally about cannabis, and help individuals identify preferred products.
HRB 613 Formulating Herbal Products using Cannabis (3 cr)
Explore the opportunities for combining cannabis with other medicinal plants to optimize cannabis’ benefits and reduce risks. Review pharmacological, toxicological and clinical research as well as the traditional use of candidate medicinal plants. Apply this information to evaluate cannabis-containing herbal products already on the market as well as to design new products. Learn to formulate a cannabis-containing multi-herb blend for a specific purpose and to explain the rationale behind the product. Emphasis is placed on designing CBD-dominant, hemp-based dietary supplements and wellness products.
HRB 614 Quality Assurance in Cannabis Products (3 cr)
Identify and evaluate the authenticity and quality of cannabis raw material, to interpret assays and specification sheets required to produce good manufacturing practice (GMP) compliant products. Learn to apply procedures associated with GMP compliance relevant to cannabis manufacturing and dispensaries to ensure the purity, strength, composition and the contamination limits to prevent adulteration.
Academic Research and Scholarship (0 cr)
This course is designed to prepare students to engage in graduate-level research and scholarship with a focus on the utilization of resources available at or through MUIH’s Sherman Cohn Library. Modules cover the Association of College and Research Libraries information literacy threshold concepts in higher education. These concepts are: Scholarship as Conversation, Research as Inquiry, Authority is Constructed and Contextual, Information Creation as a Process, Searching as Strategic Exploration, and Information Has Value.
The cannabis industry is made up of three fields – 1) medical marijuana, 2) recreational marijuana, and 3) hemp-based, CBD-dominant cannabis. Each has experienced and is projected to have continued significant growth. The increase in use and sales of cannabis nationally is driving significant job growth in the field.
Legalization and Use
As of January 2020, medical and recreational marijuana is legal in 11 states, medical marijuana only is legal in 22 states, and hemp is federally legal in all 50 states (1, 2). The 2017 National Survey on Drug Use and Health estimated that 24 million Americans above the age of 18 were users of marijuana, representing nearly 9% of the total population; marijuana use among the same group increased from 21% in 2002 to 30% in 2017 (3).
Overall Cannabis Industry Growth
New Frontier Data reports overall sales within the legalized U.S. cannabis industry, which includes both recreational and medical marijuana, were expected to reach $13.6 billion throughout 2019, a 32% increase over 2018 sales (4). Total combined U.S. legal sales are projected to continue to grow at an annual rate of 14%, reaching $30 billion in sales by 2025. Total legal recreational use sales are projected to grow 16% to $16.6 billion in sales by 2025. If the total U.S. cannabis market were to be legalized, Barclay’s (5) estimates the market could be worth $41 billion by 2028, and Cowen and Company estimates a market value of $80 billion by 2030 (6). Globally, Fortune Business Insights reports the cannabis market (including medical, recreational and hemp-based) was $10.6 billion in 2018 and projects it to reach $97.3 billion by the end of 2026, a 33% annual growth from 2019 to 2026 (7).
Medical and Recreational Marijuana Industry Growth
New Frontier Data projects combined U.S. sales of medical cannabis to grow 17% annually from $4.4 billion in 2018 to $13.1 billion in 2025 (4,8). In Maryland, sales doubled in the first year of legalization (2018-2019) and required a second round of business license applications for medical marijuana dispensaries, cultivators, and processors to meet consumer demand (9). Globally, BDS Analytics projects sales of recreational marijuana at $83 billion and medical marijuana at $19 billion by 2027.
CDB Industry Growth
Significant consumer interest exists in hemp-based and CBD-containing cannabis supplements. Hemp-derived CBD is now available in general retail channels outside of licensed cannabis dispensaries, including online, drug stores, natural products, beauty, convenience, grocery and pet stores. Research firm Brightfield Group projects the U.S. CBD industry will outpace the marijuana market and reach $23.7 billion in sales by 2023 (10). BDS Analytics forecasts U.S. CBD sales to reach $20 billion by 2024, accounting for nearly 44% of the $45 billion total forecasted cannabinoid market (11). Hemp-based cannabis sales of CBD-based supplements grew 332% from 2018 to 2019, with over $52 million in 2019 sales, making hemp-based cannabis supplements the top selling herbal supplement in the U.S. market (12). Current herbal supplement manufacturers are increasingly embracing CBD based cannabis products. The percent of natural product manufacturers selling such products doubled in the first six months of 2019, with 75% of the industry planning on launching new CBD-based products over the next two years (13).
Cannabis Industry Job Growth
Marijuana Business Daily’s 2019 Marijuana Business Factbook estimates the number of full-time workers in the U.S. marijuana industry was between 130,000 and 160,000 in 2018, increased to 175,000 to 215,000 in 2019, and will reach 385,000 to 475,000 workers by 2023 (9). BDS Analytics and Arcview estimate as many as 630,000 cannabis jobs by 2025 (13). Leafly’s Cannabis Job Count report suggests that the cannabis industry is among the largest job creation engines in the U.S (14).
The career opportunities vary based on the segment of the market (medical vs. recreational vs. hemp-based cannabis). However, all three segments demand similar knowledge and skill sets that are basic to the world of herbal supplements. Nationally based cannabis-specific hiring firm Vangst provides a benchmarking salary guide for working in the cannabis industry and the requirements for employment in each state (15).
Careers that graduates of the Post-Baccalaureate Certificate in Cannabis Science: Therapeutics, Product Design, and Quality Assurance may be qualified for include:
This program is offered in the online format. Click here to view MUIH’s definition of the online program format.
For trimester start and end dates, see the Academic Calendar.
The schedule of courses for this program is shown below:
MUIH550 Academic Research and Scholarship (0 cr)
HRB610 The Endocannabinoid System and Phytocannabinoids (3 cr)
HRB611 Cannabis Therapeutics (3 cr)
HRB612 Cannabis Dispensary Practices (3 cr)
HRB613 Formulating Herbal Products using Cannabis (3 cr)
HRB614 Quality Assurance in Cannabis Products (3 cr)
|Trimester of Entry:||Fall|
|Application Priority Deadline:||Application deadline by Trimester|
|Program Specific Requirements:||Complete Essay Questions in application:
Kathleen Warner, Ph.D.
Michael Tims, Ph.D.
Program Director, Herbal Product Design and Manufacture
Program Director, Cannabis Science: Therapeutics, Product Design and Quality Assurance
Rachel Voss, M.P.A.